

Shinsuke Fujioka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2347524/publications.pdf>

Version: 2024-02-01

91
papers

2,501
citations

279798

23
h-index

243625

44
g-index

96
all docs

96
docs citations

96
times ranked

4016
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinsonâ€™s disease. Expert Opinion on Drug Safety, 2022, 21, 137-147.	2.4	6
2	Hypertrophic pachymeningitis associated with Sjögrenâ€™s syndrome: case report and literature review. Neurologia I Neurochirurgia Polska, 2022, 56, 195-196.	1.2	2
3	Physical Activity and Its Diurnal Fluctuations Vary by Non-Motor Symptoms in Patients with Parkinsonâ€™s Disease: An Exploratory Study. Healthcare (Switzerland), 2022, 10, 749.	2.0	2
4	PLA2G6-associated neurodegeneration in four different populations-case series and literature review. Parkinsonism and Related Disorders, 2022, 101, 66-74.	2.2	4
5	Radiofrequency Vento-oral Thalamotomy for Post-stroke Focal Dystonia in a Pediatric Patient. NMC Case Report Journal, 2021, 8, 445-450.	0.5	0
6	Perry Disease: Concept of a New Disease and Clinical Diagnostic Criteria. Journal of Movement Disorders, 2021, 14, 1-9.	1.3	13
7	Meta-iodobenzylguanidine myocardial scintigraphy in Perry disease. Parkinsonism and Related Disorders, 2021, 83, 49-53.	2.2	5
8	Impact of Progression of Parkinsonâ€™s Disease on Swallowing Ability and Oral Environment. Parkinson's Disease, 2021, 2021, 1-6.	1.1	3
9	A novel diagnostic marker for progressive supranuclear palsy targeting atrophy of the subthalamic nucleus. Journal of the Neurological Sciences, 2021, 423, 117366.	0.6	3
10	DCTN1 Binds to TDP-43 and Regulates TDP-43 Aggregation. International Journal of Molecular Sciences, 2021, 22, 3985.	4.1	19
11	The impact of tube replacement timing during LCIG therapy on PEG-J associated adverse events: a retrospective multicenter observational study. BMC Neurology, 2021, 21, 242.	1.8	8
12	Personalized Medicine in Parkinsonâ€™s Disease: New Options for Advanced Treatments. Journal of Personalized Medicine, 2021, 11, 650.	2.5	5
13	Longitudinal Changes of Tongue Thickness and Tongue Pressure in Neuromuscular Disorders. BMC Neurology, 2021, 21, 302.	1.8	3
14	Behavioral profile in a Dctn1G71A knock-in mouse model of Perry disease. Neuroscience Letters, 2021, 764, 136234.	2.1	6
15	Circulatory 25(OH)D and 1,25(OH)2D as differential biomarkers between multiple system atrophy and Parkinson's disease patients. ENeurologicalSci, 2021, 25, 100369.	1.3	5
16	A refractory human T-cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis patient with lymphoma-type adult T-cell leukemia/lymphoma. Medicine (United States), 2021, 100, e27450.	1.0	4
17	Off Time Independently Affects Quality of Life in Advanced Parkinsonâ€™s Disease (APD) Patients but Not in Non-APD Patients: Results from the Self-Reported Japanese Quality-of-Life Survey of Parkinsonâ€™s Disease (JAQPAD) Study. Parkinson's Disease, 2021, 2021, 1-9.	1.1	3
18	Fluctuating pain in Parkinson's disease: Its prevalence and impact on quality of life. ENeurologicalSci, 2021, 25, 100371.	1.3	0

#	ARTICLE	IF	CITATIONS
19	Evaluation of Motor Complications in Parkinson's Disease: Understanding the Perception Gap between Patients and Physicians. <i>Parkinson's Disease</i> , 2021, 2021, 1-8.	1.1	3
20	Relationship between tongue pressure and functional oral intake scale diet type in patients with neurological and neuromuscular disorders. <i>Clinical Neurology and Neurosurgery</i> , 2020, 198, 106196.	1.4	7
21	An International Survey of Deep Brain Stimulation Utilization in Asia and Oceania: The DBS Think Tank East. <i>Frontiers in Human Neuroscience</i> , 2020, 14, 162.	2.0	18
22	How to introduce a rotigotine patch to Parkinson's disease patients taking oral dopamine agonists. <i>Clinical Neurology and Neurosurgery</i> , 2020, 199, 106266.	1.4	1
23	Global Survey on Telemedicine Utilization for Movement Disorders During the COVID-19 Pandemic. <i>Movement Disorders</i> , 2020, 35, 1701-1711.	3.9	73
24	Impact of motor and nonmotor symptoms in Parkinson disease for the quality of life: The Japanese Quality-of-Life Survey of Parkinson Disease (JAQPAD) study. <i>Journal of the Neurological Sciences</i> , 2020, 419, 117172.	0.6	17
25	Surgical management of adverse events associated with deep brain stimulation: A single-center experience. <i>SAGE Open Medicine</i> , 2020, 8, 205031212091345.	1.8	9
26	Biofeedback Core Exercise Using Hybrid Assistive Limb for Physical Frailty Patients With or Without Parkinson's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 215.	2.4	10
27	Perry disease: recent advances and perspectives. <i>Expert Opinion on Orphan Drugs</i> , 2019, 7, 253-259.	0.8	2
28	Sensitivity and specificity of cardiac 123I-MIBG scintigraphy for diagnosis of early-phase Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2019, 407, 116409.	0.6	10
29	Cerebrospinal Fluid CXCL10 as a Candidate Surrogate Marker for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis. <i>Frontiers in Microbiology</i> , 2019, 10, 2110.	3.5	17
30	Acute cholecystitis induced by surgery for levodopa-carbidopa intestinal gel therapy: Possible relationship to pre-existing gallstones. <i>Parkinsonism and Related Disorders</i> , 2018, 54, 107-109.	2.2	2
31	Multiple system atrophy and apolipoprotein E. <i>Movement Disorders</i> , 2018, 33, 647-650.	3.9	15
32	Mutations in bassoon in individuals with familial and sporadic progressive supranuclear palsy-like syndrome. <i>Scientific Reports</i> , 2018, 8, 819.	3.3	26
33	Does cigarette smoking do nothing but harm?. <i>Neurology</i> , 2018, 90, 307-308.	1.1	1
34	Caffeine and Parkinson disease. <i>Neurology</i> , 2018, 90, 205-206.	1.1	11
35	Establishing diagnostic criteria for Perry syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 482-487.	1.9	40
36	Association study between multiple system atrophy and TREM2 p.R47H. <i>Neurology: Genetics</i> , 2018, 4, e257.	1.9	9

#	ARTICLE	IF	CITATIONS
37	Modeling Parkinson's Disease and Atypical Parkinsonian Syndromes Using Induced Pluripotent Stem Cells. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3870.	4.1	10
38	Longstanding IgG4-related Ophthalmic Disease Dramatically Improved after Steroid Therapy. <i>Internal Medicine</i> , 2018, 57, 2879-2883.	0.7	4
39	A novel promising therapeutic approach for patients with ataxic disorders?. <i>Neurology</i> , 2018, 91, 541-542.	1.1	1
40	The Prevalence of Constipation and Irritable Bowel Syndrome in Parkinson's Disease Patients According to Rome III Diagnostic Criteria. <i>Journal of Parkinson's Disease</i> , 2017, 7, 353-357.	2.8	31
41	Occurrence of Crohn's disease with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017, 37, 116-117.	2.2	26
42	Serum uric acid level is linked to the disease progression rate in male patients with multiple system atrophy. <i>Clinical Neurology and Neurosurgery</i> , 2017, 158, 15-19.	1.4	6
43	Dysphagia in Perry Syndrome: Pharyngeal Pressure in Two Cases. <i>Case Reports in Neurology</i> , 2017, 9, 161-167.	0.7	2
44	Dysphagia in Multiple System Atrophy of Cerebellar and Parkinsonian Types. <i>Journal of Neurology and Neuroscience</i> , 2017, 08, .	0.4	12
45	Characteristics of tongue and pharyngeal pressure in patients with neuromuscular diseases. <i>Degenerative Neurological and Neuromuscular Disease</i> , 2017, Volume 7, 71-78.	1.3	7
46	The Risk Factors for the Wearing-off Phenomenon in Parkinson's Disease in Japan: A Cross-sectional, Multicenter Study. <i>Internal Medicine</i> , 2017, 56, 1961-1966.	0.7	19
47	Idiopathic remitting seronegative symmetrical synovitis with pitting edema syndrome associated with bilateral pleural and pericardial effusions: a case report. <i>Journal of Medical Case Reports</i> , 2016, 10, 198.	0.8	12
48	MAPT haplotype diversity in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2016, 30, 40-45.	2.2	23
49	Hospital-based study on emergency admission of patients with Parkinson's disease. <i>ENeurologicalSci</i> , 2016, 4, 19-21.	1.3	24
50	Tremor in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2016, 27, 93-97.	2.2	17
51	The impact of early morning off in Parkinson's disease on patient quality of life and caregiver burden. <i>Journal of the Neurological Sciences</i> , 2016, 364, 1-5.	0.6	24
52	Impulsive and compulsive parkin disease. <i>Neurology</i> , 2016, 87, 1426-1427.	1.1	1
53	A case of sudden deterioration in Parkinson disease. <i>Neurology</i> , 2016, 87, 1422-1422.	1.1	2
54	Cancer in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 31, 28-33.	2.2	41

#	ARTICLE	IF	CITATIONS
55	VI. Emergency and Perioperative Management of the Parkinson's Disease Patients. The Journal of the Japanese Society of Internal Medicine, 2015, 104, 1578-1584.	0.0	0
56	Clinical Correlations With Lewy Body Pathology in <i>LRRK2</i> -Related Parkinson Disease. JAMA Neurology, 2015, 72, 100.	9.0	272
57	A novel tau mutation, p.K317N, causes globular glial tauopathy. Acta Neuropathologica, 2015, 130, 199-214.	7.7	38
58	Three sib-pairs of autopsy-confirmed progressive supranuclear palsy. Parkinsonism and Related Disorders, 2015, 21, 101-105.	2.2	42
59	Clinical presentation of a patient with SLC20A2 and THAP1 deletions: Differential diagnosis of oromandibular dystonia. Parkinsonism and Related Disorders, 2015, 21, 329-331.	2.2	5
60	Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. Nature Communications, 2015, 6, 7247.	12.8	170
61	Impact of insufficient drug efficacy of antiparkinson agents on patient's quality of life: a cross-sectional study. BMC Neurology, 2015, 15, 105.	1.8	7
62	Role for the microtubule-associated protein tau variant p.A152T in risk of α -synucleinopathies. Neurology, 2015, 85, 1680-1686.	1.1	31
63	Impulse control disorders and punding in Perry syndrome. Parkinsonism and Related Disorders, 2015, 21, 1381-1382.	2.2	12
64	Hippocampal sclerosis in Lewy body disease is a TDP-43 proteinopathy similar to FTLTDP Type A. Acta Neuropathologica, 2015, 129, 53-64.	7.7	67
65	<i>LRRK2</i> exonic variants and risk of multiple system atrophy. Neurology, 2014, 83, 2256-2261.	1.1	46
66	Analysis of COQ2 gene in multiple system atrophy. Molecular Neurodegeneration, 2014, 9, 44.	10.8	40
67	<i>DCTN1</i> Mutations and Progressive Supranuclear Palsy-Like Phenotype. JAMA Neurology, 2014, 71, 655.	9.0	3
68	Diagnosis and management of Marchiafava-Bignami disease: a review of CT/MRI confirmed cases. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 168-173.	1.9	106
69	Familial Progressive Supranuclear Palsy: A Literature Review. Neurodegenerative Diseases, 2014, 13, 180-182.	1.4	14
70	Update on novel familial forms of Parkinson's disease and multiple system atrophy. Parkinsonism and Related Disorders, 2014, 20, S29-S34.	2.2	84
71	A familial form of parkinsonism, dementia, and motor neuron disease: A longitudinal study. Parkinsonism and Related Disorders, 2014, 20, 1129-1134.	2.2	6
72	Parkinsonian syndrome in familial frontotemporal dementia. Parkinsonism and Related Disorders, 2014, 20, 957-964.	2.2	140

#	ARTICLE	IF	CITATIONS
73	Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer's disease. <i>Brain</i> , 2014, 137, 1533-1549.	7.6	100
74	Three families with Perry syndrome from distinct parts of the world. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 884-888.	2.2	24
75	Parkinsonian features in hereditary diffuse leukoencephalopathy with spheroids (HDLS) and CSF1R mutations. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 869-877.	2.2	119
76	TARDBP mutations in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 312-315.	2.2	49
77	Sequence variants in eukaryotic translation initiation factor 4-gamma (eIF4G1) are associated with Lewy body dementia. <i>Acta Neuropathologica</i> , 2013, 125, 425-438.	7.7	20
78	An adult-onset leukoencephalopathy with axonal spheroids and pigmented glia accompanied by brain calcifications. <i>Journal of Neurology</i> , 2013, 260, 2665-2668.	3.6	22
79	Progressive Supranuclear Palsy: High-Field-Strength MR Microscopy in the Human Substantia Nigra and Globus Pallidus. <i>Radiology</i> , 2013, 266, 280-288.	7.3	26
80	Similarities between familial and sporadic autopsy-proven progressive supranuclear palsy. <i>Neurology</i> , 2013, 80, 2076-2078.	1.1	31
81	Clinicopathologic variability of the <i>GRN</i> A9D mutation, including amyotrophic lateral sclerosis. <i>Neurology</i> , 2013, 80, 1771-1777.	1.1	24
82	Update on Genetics of Parkinsonism. <i>Neurodegenerative Diseases</i> , 2012, 10, 257-260.	1.4	23
83	Autosomal dominant Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012, 18, S7-S10.	2.2	39
84	A novel de novo pathogenic mutation in the <i>CACNA1A</i> gene. <i>Movement Disorders</i> , 2012, 27, 1578-1579.	3.9	3
85	MRI characteristics and scoring in HDLS due to <i>CSF1R</i> gene mutations. <i>Neurology</i> , 2012, 79, 566-574.	1.1	153
86	Clinical Aspects of Familial Forms of Frontotemporal Dementia Associated with Parkinsonism. <i>Journal of Molecular Neuroscience</i> , 2011, 45, 359-365.	2.3	17
87	Autosomal dominant cerebellar ataxia type I: A review of the phenotypic and genotypic characteristics. <i>Orphanet Journal of Rare Diseases</i> , 2011, 6, 33.	2.7	68
88	A case of encephalitis lethargica associated with relapsing polychondritis. <i>Movement Disorders</i> , 2008, 23, 2421-2423.	3.9	11
89	Acute motor sensory axonal neuropathy associated with Henoch-Schönlein purpura. <i>Journal of the Neurological Sciences</i> , 2007, 263, 169-173.	0.6	8
90	Partial but Rapid Recovery from Paralysis after Immunomodulation during Early Stage of Neuralgic Amyotrophy. <i>European Neurology</i> , 2006, 55, 227-229.	1.4	35

#	ARTICLE	IF	CITATIONS
91	Diffusion-weighted MRI in familial Creutzfeldtâ€“Jakob disease with the codon 200 mutation in the prion protein gene. Journal of the Neurological Sciences, 2005, 232, 45-49.	0.6	18